Biomarker-Driven Lung Cancer

EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases

According to findings presented by Martin Reck, MD, PhD, at the 2018 European Lung Cancer Conference, the frontline regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel has became a potential new standard of care for the treatment of patients with metastatic nonsquamous non–small cell lung cancer.

EGFR+ NSCLC

According to 3-year survival findings from the phase II POPLAR study, anti PD-L1 immunotherapy with atezolizumab (Tecentriq) demonstrated strong superiority to docetaxel in locally advanced or metastatic non–small cell lung cancer.

Overall survival was improved with the&nbsp;PD-1 inhibitor pembrolizumab versus chemotherapy as a frontline treatment for patients with&nbsp;locally advanced or metastatic non&ndash;small cell lung cancer and a PD-L1 expression level &ge;1%, according to findings from the phase III KEYNOTE-042 trial.<br /> &nbsp;

Non-Driver NSCLC: Practice Considerations